Bayer Zydus Pharma Profile
Key Indicators
- Authorised Capital ₹ 100.00 Cr
as on 17-11-2024
- Paid Up Capital ₹ 50.00 Cr
as on 17-11-2024
- Company Age 13 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -0.76%
(FY 2023)
- Profit 232.18%
(FY 2023)
- Ebitda 299.87%
(FY 2023)
- Net Worth 14.94%
(FY 2023)
- Total Assets 11.66%
(FY 2023)
About Bayer Zydus Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 100.00 Cr and a paid-up capital of Rs 50.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Bayer Zydus Pharma Private Limited India is Hemal Bhavsar as COMPANY SECRETARY. Kunal Jha and Shweta Rai serve as directors at the Company.
- CIN/LLPIN
U24233MH2011PTC213118
- Company No.
213118
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Feb 2011
- Date of AGM
13 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Bayer Zydus Pharma?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shweta Rai  | Managing Director | 27-Jan-2024 | Current |
| Hemal Bhavsar | Company Secretary | 15-Dec-2021 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kunal Jha | Director | 03-May-2024 | Current |
Financial Performance and Corporate Structure Insights of Bayer Zydus Pharma.
Bayer Zydus Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 0.76% decrease. The company also saw a substantial improvement in profitability, with a 232.18% increase in profit. The company's net worth Soared by an impressive increase of 14.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bayer Zydus Pharma?
In 2023, Bayer Zydus Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bayer Pharmaceuticals Private LimitedActive 26 years 4 monthsKunal Jha and Shweta Rai are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bayer Zydus Pharma?
Bayer Zydus Pharma has a workforce of 713 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bayer Zydus Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bayer Zydus Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
